SUBOXONE
What it isBuprenorphine partial mu agonist plus poorly absorbed sublingual naloxone; maintenance treatment for opioid use disorder.
Why this oneThe naloxone is a misuse deterrent: negligible sublingually, but it precipitates withdrawal if the product is dissolved and injected.
What limits itStarting it too soon after a full agonist precipitates withdrawal. Benzodiazepines and other sedatives still increase respiratory risk.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Opioid dependence (induction) | Adults (short-acting opioid dependence) | Day 1: up to 8 mg/2 mg (divided doses); Day 2: up to 16 mg/4 mg QD | — | 16 mg/4 mg on Day 2 |
| Opioid dependence (maintenance) | Adults | Titrate from induction dose | 4 mg/1 mg to 24 mg/6 mg QD | 24 mg/6 mg QD |
Renal Undefined
Hepatic Not recommended in severe hepatic impairment; may not be appropriate in moderate hepatic impairment
Pregnancy Limited data do not indicate increased malformation risk from buprenorphine; prolonged use can cause neonatal opioid withdrawal syndrome; dose adjustments may be needed.
Lactation Buprenorphine present in low levels in human milk; oral naloxone absorption limited; monitor infant.
NO BOXED WARNINGS

Open Buprenorphine/ naloxone in the interactive console ↗
